Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models
Authors:
- 14 March 2017
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 48 (2) , 148-156
Abstract
1. Dalbavancin, a lipoglycopeptide, is approved for treating gram-positive bacterial infections. Area under plasma concentration versus time curve (AUCinf) of dalbavancin is a key parameter and AUCinf/MIC ratio is a critical pharmacodynamic marker. 2. Using end of intravenous infusion concentration (i.e. Cmax) Cmax versus AUCinf relationship for dalbavancin was established by regression analyses (i.e. linear, log–log, log–linear and power models) using 21 pairs of subject data. 3. The predictions of the AUCinf were performed using published Cmax data by application of regression equations. The quotient of observed/predicted values rendered fold difference. The mean absolute error (MAE)/root mean square error (RMSE) and correlation coefficient (r) were used in the assessment. 4. MAE and RMSE values for the various models were comparable. The Cmax versus AUCinf exhibited excellent correlation (r > 0.9488). The internal data evaluation showed narrow confinement (0.84–1.14-fold difference) with a RMSE < 10.3%. The external data evaluation showed that the models predicted AUCinf with a RMSE of 3.02–27.46% with fold difference largely contained within 0.64–1.48. 5. Regardless of the regression models, a single time point strategy of using Cmax (i.e. end of 30-min infusion) is amenable as a prospective tool for predicting AUCinf of dalbavancin in patients.Keywords
This publication has 23 references indexed in Scilit:
- Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration dataBiopharmaceutics & Drug Disposition, 2015
- Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12–17 Years of AgeThe Pediatric Infectious Disease Journal, 2015
- Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection modelInternational Journal of Antimicrobial Agents, 2013
- New LipoglycopeptidesDrugs, 2010
- In Vivo Pharmacodynamic Activity of the Glycopeptide DalbavancinAntimicrobial Agents and Chemotherapy, 2007
- Bactericidal Activity and Resistance Development Profiling of DalbavancinAntimicrobial Agents and Chemotherapy, 2007
- Infections associated with orthopedic implantsCurrent Opinion in Infectious Diseases, 2006
- Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptideJournal of Antimicrobial Chemotherapy, 2005
- Antistaphylococcal Activity of Dalbavancin, an Experimental GlycopeptideAntimicrobial Agents and Chemotherapy, 2005
- Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004